Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-SMT487 in symptomatic malignant carcinoid tumors
NCT00696930Phase 2Withdrawn
- Sponsor
- Molecular Insights Pharmaceuticals
- Start
- Jun 2008
- Primary completion
- Jun 2008
- Modality
- Peptide-Drug Conjugates
01
Overview
Phase 2, open-label, single-arm trial of yttrium (90Y) edotreotide in Malignant carcinoid tumor (NET), sponsored by Molecular Insights Pharmaceuticals. Planned start Jun 2008; status: withdrawn.
02
Drugs
yttrium (90Y) edotreotide
03
Conditions
Malignant carcinoid tumor (NET)
Beyond the preview
Go deeper on NCT00696930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00696930.